Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: Analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database

Journal of Clinical Oncology

Volumn 34, Issue 8, 2016, Pages 843-853

  Shah, Manish A ^a   Renfro, Lindsay A ^b   Allegra, Carmen J ^c   André, Thierry ^d   De Gramont, Aimery ^e   Schmoll, Hans Joachim ^f   Haller, Daniel G ^g   Alberts, Steven R ^b   Yothers, Greg ^h   Sargent, Daniel J ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d HÔPITAL SAINT ANTOINE   (France)

^e Franco British Institute   (France)

^f MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK REDUCTION; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; BIOASSAY; COLONIC NEOPLASMS; FACTUAL DATABASE; MIDDLE AGED; MORTALITY; PREVENTION AND CONTROL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DATABASES, FACTUAL; ENDPOINT DETERMINATION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84962512686     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.0558     Document Type: Article

References (19)

1. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]: International Agency for Research on Cancer 2013.
2. André T, Boni C, Mounedji-Boudiaf L, et al: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
3. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
4. Shi Q, Andre T, Grothey A, et al: Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: Evidence of stage migration from the ACCENT database. J Clin Oncol 31:3656-3663, 2013
5. Sargent D, Sobrero A, Grothey A, et al: Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 27:872-877, 2009
6. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
7. Sargent D, Shi Q, Yothers G, et al; Adjuvant Colon Cancer End-points (ACCENT) Group: Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12, 676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47:990-996, 2011
8. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007
9. Allegra CJ, Yothers G, O'Connell MJ, et al: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 29:11-16, 2011
10. Haller DG, Tabernero J, Maroun J, et al: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465-1471, 2011
11. Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307:1383-1393, 2012
12. Müller HG, Wang JL: Hazard rate estimation under random censoring with varying kernels and bandwidths. Biometrics 50:61-76, 1994
13. Gilbert PB, Wei LJ, Kosorok MR, et al: Simultaneous inferences on the contrast of two hazard functions with censored observations. Biometrics 58:773-780, 2002
14. Arriagada R, Dunant A, Pignon JP, et al: Longterm results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 28:35-42, 2010
15. Fossao SD, Gilbert E, Dores GM, et al: Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99:533-544, 2007
16. Labianca R, Nordlinger B, Beretta GD, et al; ESMO Guidelines Working Group: Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi64-vi72, 2013
17. Meyerhardt JA, Mangu PB, Flynn PJ, et al; American Society of Clinical Oncology: Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 31:4465-4470, 2013
18. Benson AB III, Venook AP, Bekaii-Saab T, et al; National Comprehensive Cancer Network: Colon cancer, version 3.2014. J Natl Compr Canc Netw 12:1028-1059, 2014
19. Cancer Care Ontario: Colorectal Cancer Follow-up Care Pathway. Disease Pathway Management Secretariat. Version 2013. 05. https://www.cancercare.on. ca/common/pages/UserFile. aspx?fileId=298461